Effects of PACAP on Dry Eye Symptoms, and Possible Use for Therapeutic Application

被引：0
作者：
Seiji Shioda
Fumiko Takenoya
Takahiro Hirabayashi
Nobuhiro Wada
Tamotsu Seki
Naoko Nonaka
Tomoya Nakamachi
机构：
[1] Hoshi University School of Pharmacy and Pharmaceutical Sciences,Global Research Center for Innovative Life Science
[2] Showa University School of Medicine,Department of Anatomy and Ophthalmology
[3] Showa University School of Dentistry,Department of Oral Anatomy and Developmental Biology
[4] University of Toyama,Laboratory of Regulatory Biology, Graduate School of Science and Engineering
来源：
Journal of Molecular Neuroscience | 2019年 / 68卷
关键词：
PACAP; Neuroprotective function; Dry eye; Aging;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a 27- or 38-amino acid neuropeptide, which belongs to the vasoactive intestinal polypeptide/glucagon/secretin family of peptides. PACAP and its three receptor subtypes are expressed in neural tissues and in the eye, including the retina, cornea, and lacrimal gland. PACAP is known to exert pleiotropic effects on the central nervous system and in eye tissues where it plays important roles in protecting against dry eye. This review provides an overview of current knowledge regarding dry eye symptoms in aged animals and humans and the protective effects, mechanisms of action. In addition, we also refer to the development of a new preventive/therapeutic method by PACAP of dry eye patients.
引用
收藏
页码：420 / 426
页数：6
相关论文
共 299 条
  • [1] Arimura A(1995)Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors: neuroendocrine and endocrine interaction Front Neuroendocrinol 16 53-88
  • [2] Shioda S(2011)Evidence for a vascular factor in migraine Ann Neurol 69 635-645
  • [3] Asghar MS(2014)Androgen deficiency and dry eye syndrome in the aging male Invest Ophthalmol Vis Sci 55 5046-5053
  • [4] Hansen AE(1993)Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier J Pharmacol Exp Ther 267 690-696
  • [5] Amin FM(1996)Transport of pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier and the prevention of ischemia-induced death of hippocampal neurons Ann N Y Acad Sci 805 270-277
  • [6] van der Geest RJ(2004)Animal models of dry eye: a critical assessment of opportunities and limitations Invest Ophthalmol Vis Sci 45 1641-1646
  • [7] Koning P(2007)The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers Regul Pept 140 185-191
  • [8] Larsson HBW(2005)Computer vision syndrome: a review Surv Ophthalmol 50 253-262
  • [9] Olesen J(2009)The in vivo effect of VIP, PACAP-38 and PACAP-27 and mRNA expression of their receptors in rat middle meningeal artery Cephalalgia 29 837-847
  • [10] Ashina M(2005)Pituitary adenylate cyclase-activating polypeptide (PACAP) can act as determinant of the tyrosine hydroxylase phenotype of dopaminergic cells during retina development Brain Res Dev Brain Res 156 193-201
12345678910